This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Balch, G. C. Articles by Kelley, M. C. Search for Related Content PubMed PubMed Citation Articles by Balch, G. C. Articles by Kelley, M. C. Related Collections Sentinel lymph node

Lymphatic Mapping and Sentinel Lymphadenectomy After Preoperative Therapy for Stage II and III Breast Cancer

From the Division of Surgical Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.

Correspondence: Address correspondence and reprint requests to: Mark C. Kelley, MD, Vanderbilt University Medical Center, 597 Preston Research Building, 21st Ave. South, Nashville, TN 37232-6860; Fax: 615-343-4598; E-mail: mark.kelley{at}mcmail.vanderbilt.edu

Background: We evaluated the accuracy of sentinel lymph node dissection (SLND) in patients with stage II and III breast cancer who had received preoperative therapy.

Methods: A prospective clinical trial evaluated 122 patients who had SLND followed by axillary lymph node dissection. Thirty-two women had stage II or III breast cancer and received preoperative doxorubicin-based chemotherapy or paclitaxel and radiotherapy.

Results: A sentinel lymph node (SLN) was identified in 31 (97%) of 32 patients. The SLN predicted the status of the axillary nodes in 30 (97%) of 31 patients. Eighteen (58%) of 31 had metastases in the SLN. Eighteen of 19 patients with axillary metastases had a tumor-positive SLN (sensitivity, 95%; false-negative rate, 5%). Eight (44%) of 18 women with metastases in the SLN also had metastases in 1 or more nonsentinel nodes.

Conclusions: In this relatively small study, the accuracy of SLND in women with stage II or III breast cancer treated with preoperative therapy was similar to that achieved in early-stage breast cancer. If these results are confirmed in a larger cohort, it may be feasible to substitute SLND for routine axillary lymph node dissection in this population. This approach could reduce the morbidity of surgical therapy while preserving the accuracy of axillary staging and maintaining regional control in this high-risk population.

Key Words: Breast cancer • Lymphatic mapping • Sentinel lymph node dissection • Preoperative radiotherapy • Preoperative chemotherapy

This article has been cited by other articles:

				B. J. Grube, C. J. Christy, D. Black, M. Martel, L. Harris, J. Weidhaas, M. P. DiGiovanna, G. Chung, M. M. Abu-Khalaf, K. D. Miller, et al. Breast Sentinel Lymph Node Dissection Before Preoperative Chemotherapy Arch Surg, July 1, 2008; 143(7): 692 - 700. [Abstract] [Full Text] [PDF]

				P. Gimbergues, C. Abrial, X. Durando, G. Le Bouedec, F. Cachin, F. Penault-Llorca, M. A. Mouret-Reynier, F. Kwiatkowski, J. Maublant, A. Tchirkov, et al. Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy Is Accurate in Breast Cancer Patients with a Clinically Negative Axillary Nodal Status at Presentation Ann. Surg. Oncol., May 1, 2008; 15(5): 1316 - 1321. [Abstract] [Full Text] [PDF]

				E. A. Newman, M. S. Sabel, A. V. Nees, A. Schott, K. M. Diehl, V. M. Cimmino, A. E. Chang, C. Kleer, D. F. Hayes, and L. A. Newman Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation Ann. Surg. Oncol., October 1, 2007; 14(10): 2946 - 2952. [Abstract] [Full Text] [PDF]

				M. C. van Rijk, O. E. Nieweg, E. J. T. Rutgers, H. S. A. Oldenburg, R. V. Olmos, C. A. Hoefnagel, and B. B. R. Kroon Sentinel Node Biopsy Before Neoadjuvant Chemotherapy Spares Breast Cancer Patients Axillary Lymph Node Dissection Ann. Surg. Oncol., April 1, 2006; 13(4): 475 - 479. [Abstract] [Full Text] [PDF]

				C. E. Cox, J. M. Cox, L. B. White, N. G. Stowell, J. D. Clark, N. Allred, M. Meyers, E. Dupont, B. Furman, and S. Minton Sentinel Node Biopsy Before Neoadjuvant Chemotherapy for Determining Axillary Status and Treatment Prognosis in Locally Advanced Breast Cancer Ann. Surg. Oncol., April 1, 2006; 13(4): 483 - 490. [Abstract] [Full Text] [PDF]

				G. H. Lyman, A. E. Giuliano, M. R. Somerfield, A. B. Benson III, D. C. Bodurka, H. J. Burstein, A. J. Cochran, H. S. Cody III, S. B. Edge, S. Galper, et al. American Society of Clinical Oncology Guideline Recommendations for Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer J. Clin. Oncol., October 20, 2005; 23(30): 7703 - 7720. [Abstract] [Full Text] [PDF]

				A. Khan, M. S. Sabel, A. Nees, K. M. Diehl, V. M. Cimmino, C. G. Kleer, A. F. Schott, D. F. Hayes, A. E. Chang, and L. A. Newman Comprehensive Axillary Evaluation in Neoadjuvant Chemotherapy Patients With Ultrasonography and Sentinel Lymph Node Biopsy Ann. Surg. Oncol., September 1, 2005; 12(9): 697 - 704. [Abstract] [Full Text] [PDF]

				H. M. Kuerer and L. A. Newman Lymphatic Mapping and Sentinel Lymph Node Biopsy for Breast Cancer: Developments and Resolving Controversies J. Clin. Oncol., March 10, 2005; 23(8): 1698 - 1705. [Full Text] [PDF]

				A. Luini, G. Gatti, B. Ballardini, S. Zurrida, V. Galimberti, P. Veronesi, A. R. Vento, S. Monti, G. Viale, G. Paganelli, et al. Development of axillary surgery in breast cancer Ann. Onc., February 1, 2005; 16(2): 259 - 262. [Abstract] [Full Text] [PDF]

				S. E. Singletary Candidates for Minimally Invasive Therapy of Breast Cancer: Redefining the Standards Ann. Surg. Oncol., July 1, 2003; 10(6): 591 - 592. [Full Text] [PDF]